Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Theratechnologies Inc. (T:TH)

Business Focus: Biopharmaceuticals

Jul 10, 2024 07:30 am ET
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Jun 26, 2024 07:30 am ET
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
May 23, 2024 05:00 pm ET
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced Phase 1 data demonstrating signs of...
May 09, 2024 04:30 pm ET
Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of...
May 02, 2024 07:30 am ET
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy,...
Apr 15, 2024 04:15 pm ET
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024...
Apr 11, 2024 07:30 am ET
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul...
Apr 10, 2024 07:30 am ET
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Apr 08, 2024 04:30 pm ET
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the...
Apr 05, 2024 11:00 am ET
Theratechnologies Appoints Elina Tea to its Board of Directors
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief...
Apr 03, 2024 07:30 am ET
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
Mar 28, 2024 07:30 am ET
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced two posters will be presented at the...
Mar 22, 2024 09:36 am ET
Theratechnologies Announces Update on its Preclinical Oncology Research Program
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical...
Mar 21, 2024 08:00 pm ET
Theratechnologies Appoints Jordan Zwick to its Board of Directors
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief...
Mar 21, 2024 07:30 am ET
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced moving to the next dose level in Part 3 of...
Feb 29, 2024 04:34 pm ET
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from...
Feb 27, 2024 07:30 am ET
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug...
Feb 21, 2024 07:30 am ET
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Feb 20, 2024 07:30 am ET
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the publication of a peer-reviewed article...
Feb 15, 2024 07:30 am ET
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced completion of enrollment of the first six...
Feb 06, 2024 07:30 am ET
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
Jan 24, 2024 07:00 am ET
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the U.S. Food and Drug Administration...
Jan 23, 2024 07:30 am ET
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, has received correspondence from the U.S. Food and Drug...
Jan 02, 2024 07:30 am ET
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has filed a supplemental...
Dec 21, 2023 03:09 pm ET
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
MONTREAL, Dec. 21, 2023 /CNW/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-3.
Dec 21, 2023 03:09 pm ET
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
MONTREAL, Dec. 21, 2023 /PRNewswire/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-3.
Dec 13, 2023 07:30 am ET
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug...
Nov 24, 2023 07:30 am ET
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research...
Oct 31, 2023 12:34 pm ET
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced...
Oct 26, 2023 08:00 am ET
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has priced its previously announced...
Oct 25, 2023 04:13 pm ET
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering...
Oct 24, 2023 07:00 am ET
Theratechnologies Announces Operational Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced further changes to its operations that...
Oct 19, 2023 07:30 am ET
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today shared data demonstrating the cost-effectiveness of...
Oct 16, 2023 07:30 am ET
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has finalized all documentation...
Oct 13, 2023 07:30 am ET
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data in a poster session at ID Week 2023...
Oct 13, 2023 07:00 am ET
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced results from a study evaluating an...
Oct 12, 2023 07:30 am ET
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3...
Oct 04, 2023 07:30 am ET
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the U.S. Food and Drug Administration...
Sep 26, 2023 07:30 am ET
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Sep 25, 2023 07:30 am ET
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has reached an agreement in...
Sep 25, 2023 07:00 am ET
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has filed a supplemental...
Sep 20, 2023 07:00 am ET
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Paul Lévesque, President and...
Sep 18, 2023 04:15 pm ET
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results...
Sep 07, 2023 01:57 pm ET
Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Lévesque, President and Chief...
Sep 05, 2023 07:00 am ET
Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company expects to report...
Aug 30, 2023 10:34 am ET
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U.S.-based clinical...
Aug 21, 2023 03:24 pm ET
Toronto Stock Exchange, Theratechnologies Inc., View From The C-Suite
TORONTO, Aug. 21, 2023 /CNW/ - Paul Lévesque, President and Chief Executive Officer, Hamilton Thorne Ltd. ("Theratechnologies", the "Company", or "we") (TSX: TH) shares his Company's story in an interview with TMX Group.
Jul 31, 2023 07:00 am ET
Theratechnologies Completes 1-for-4 Reverse Stock Split
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the...
Jul 28, 2023 04:44 pm ET
Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it entered into an agreement...
Jul 21, 2023 07:00 am ET
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Gary Littlejohn has resigned from...
Jul 20, 2023 07:00 am ET
Theratechnologies Announces 1-for-4 Reverse Stock Split
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that its Board of Directors...
Jul 12, 2023 07:30 am ET
Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Jun 30, 2023 08:09 am ET
Canadian Investment Regulatory Organization Trading Halt - TH.DB.U
TORONTO, June 30, 2023 /CNW/ - The following issues have been halted by CIRO:
Jun 29, 2023 07:30 am ET
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and...
Jun 22, 2023 07:30 am ET
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it drew down on its second...
Jun 12, 2023 07:30 am ET
Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will hold a video conference call on Tuesday, June 13,...
Jun 02, 2023 12:15 pm ET
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the U.S. Food and Drug Administration...
May 25, 2023 05:31 pm ET
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1...
May 19, 2023 05:11 pm ET
Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.
/NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/
May 09, 2023 12:01 pm ET
Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of...
May 04, 2023 07:30 am ET
Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data from a landmark study in which the...
Apr 18, 2023 09:00 am ET
Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the...
Apr 18, 2023 07:30 am ET
Theratechnologies to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre.
Apr 12, 2023 07:30 am ET
Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Apr 03, 2023 07:30 am ET
Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter...
Mar 14, 2023 06:42 pm ET
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new data will be presented...
Mar 07, 2023 06:00 am ET
Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the...
Feb 28, 2023 07:30 am ET
Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Feb 28, 2023 06:30 am ET
Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has entered into a first...
Feb 22, 2023 05:30 pm ET
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may...
Feb 16, 2023 07:30 am ET
Theratechnologies Announces Path to Resume TH1902 Clinical Development
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and...
Feb 14, 2023 05:00 pm ET
Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth...
Jan 04, 2023 07:45 am ET
Open Letter to Shareholders from CEO Paul Levesque
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has...
Dec 01, 2022 06:30 pm ET
Theratechnologies Announces Update from Ongoing TH1902 Study
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the...
Oct 26, 2022 07:30 am ET
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies reports data from a tissue microarrays (TMAs) study...
Oct 13, 2022 07:30 am ET
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...
Oct 12, 2022 07:30 am ET
Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from...
Oct 03, 2022 03:09 pm ET
Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the United States Food and Drug...
Sep 26, 2022 07:30 am ET
Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter...
Sep 19, 2022 04:15 pm ET
Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief...
Sep 12, 2022 07:30 am ET
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the publication of a preclinical study...
Aug 02, 2022 07:30 am ET
Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief...
Jul 28, 2022 11:19 am ET
Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced data from two poster presentations at the...
Jul 27, 2022 06:47 pm ET
Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has received funding of $40...
Jul 14, 2022 07:30 am ET
Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
Theratechnologies Inc. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for...
Jul 14, 2022 06:30 am ET
Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today provided an update on the dose escalation portion of...
Jul 13, 2022 07:40 am ET
Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has received a binding commitment...
Jul 12, 2022 07:30 am ET
CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN $2 million of funding for a collaborative research project that aims to demonstrate the efficacy and safety of a potential innovative treatment for...
Jul 07, 2022 07:30 am ET
Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter...
May 31, 2022 07:32 am ET
Theratechnologies Announces New Head of Investor Relations
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDonald has joined the team as...
May 10, 2022 10:47 am ET
Appointments in Conjunction With Theratechnologies Annual Meeting
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today held its annual meeting of shareholders. As part of...
May 10, 2022 07:30 am ET
Theratechnologies Initiates Basket Portion of TH1902 First-in-Human Study in Advanced Resistant Malignancies
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket...
Apr 27, 2022 07:30 am ET
Theratechnologies to Focus Its Commercialization Activities on the North American Territory
Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus its commercialization...
Apr 27, 2022 07:30 am ET
THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY
MONTREAL, April 27, 2022 /CNW Telbec/ - Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus its commercialization activities on the North American territory only and, as a result, will cease its Trogarzo® commercialization operations in Europe. The Company has sent a notice of termination to TaiMed Biologics Inc. (TaiMed) as per our contractual obligations and will return the European commercialization rights to Trogarzo® for Tai
Apr 27, 2022 07:30 am ET
THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY
MONTREAL, April 27, 2022 /PRNewswire/ - Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus its commercialization activities on the North American territory only and, as a result, will cease its Trogarzo® commercialization operations in Europe. The Company has sent a notice of termination to TaiMed Biologics Inc. (TaiMed) as per our contractual obligations and will return the European commercialization rights to Trogarzo® for Tai
Apr 25, 2022 04:16 pm ET
Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in Bloom...
Apr 13, 2022 07:30 am ET
Theratechnologies Reports Financial Results for First Quarter Fiscal 2022 and Provides Business Update
Onboarding of commercial field force ongoing and to be fully completed by the end of April, 2022 MONTREAL, April 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...
Apr 08, 2022 01:00 pm ET
Theratechnologies Presents New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative Breast and Ovarian Cancers AACR An
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three...
Mar 31, 2022 05:05 pm ET
Theratechnologies to Announce Financial Results for Its First Quarter 2022
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its first quarter...
Mar 08, 2022 04:31 pm ET
Theratechnologies to Present Three Posters at AACR Including New In Vivo TH1902 Preclinical Data Demonstrating Tumor Growth Inhibition of Human Cancer Stem-Like Cells (CD133+) in Both Triple-Negative
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that three poster abstracts have been...
Feb 24, 2022 07:30 am ET
Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update
Company announces revenue guidance of US$79M to US$84M for Fiscal 2022 MONTREAL, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the...
Feb 16, 2022 07:30 am ET
Theratechnologies Presents Results From Trogarzo® IV Push Administration Study at CROI 2022
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the presentation of positive results from...
Feb 15, 2022 07:30 am ET
Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial...
Feb 10, 2022 07:00 am ET
Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its fourth quarter...
Dec 06, 2021 11:52 am ET
Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV
Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the submission of a supplemental biologics...
Nov 26, 2021 01:06 pm ET
Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it was awarded of the 2021 Innovation...
Nov 03, 2021 07:30 am ET
Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer,...
Oct 26, 2021 02:00 am ET
Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has reached an agreement with the Italian...
Oct 22, 2021 09:15 am ET
Theratechnologies Announces Publication in Frontiers in Oncology Journal Highlighting SORT1+ Technology™ for Targeting SORT1-Mediated Vasculogenic Mimicry
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the publication of a peer-reviewed article...
Oct 13, 2021 07:00 am ET
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for its...
Oct 06, 2021 08:30 am ET
Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Christian Marsolais, Ph.D., Senior Vice President and...
Sep 29, 2021 08:30 am ET
Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its third quarter...
Sep 22, 2021 08:08 am ET
Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that a study evaluating an intravenous...
Sep 16, 2021 09:02 am ET
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer,...
Aug 13, 2021 09:08 am ET
Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today the publication of data from its preclinical...
Aug 04, 2021 08:00 am ET
Theratechnologies to Present at the Canaccord Genuity 41st Annual Growth Conference
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer...
Jul 23, 2021 07:30 pm ET
Theratechnologies Establishes New At-The-Market Facility
MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from treasury (the "Common Shares") to the public at the Company's sole discretion and at the prevailing market price. Sales of the Common Shares under the ATM program will be made pursuant to the terms o
Jul 15, 2021 07:00 am ET
Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH
Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported financial results for the second quarter ended...
Jun 30, 2021 11:28 am ET
CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021
In a release issued this morning, Wednesday, June 30, 2021, under the same headline, by Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), please note that in the last sentence of the first paragraph, the date should be Thursday, July 15, 2021, not...
Jun 30, 2021 07:30 am ET
Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second...
Jun 23, 2021 07:30 am ET
Theratechnologies Appoints New Board Member
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Frank Holler as a new independent...
Jun 21, 2021 09:00 am ET
Theratechnologies Announces New Preclinical Findings for Its Lead Investigational Peptide-Drug Conjugate TH1902 for the Potential Treatment of Metastatic Cancers
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced new preclinical in vivo findings on the anti-metastatic...
Jun 10, 2021 04:01 pm ET
Theratechnologies to Host Key Opinion Leader Event to Discuss its SORT1+ Technology™ for the Treatment of All Sortilin-Expressing Cancers
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will host a key opinion leader (KOL) webinar on the...
May 31, 2021 08:00 am ET
Theratechnologies Hires Vice President, Human Resources
Theratechnologies Inc. (Theratechnologies, or the Company (TSX: TH) (NASDAQ: THTX)), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Mr. André Dupras is joining the...
May 20, 2021 07:30 am ET
Theratechnologies Announces Results From Two Posters Presented at ACTHIV 2021 Annual Meeting Highlighting Positive Patient Experience With Trogarzo®
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported on positive results presented in two separate...
May 18, 2021 09:24 am ET
Theratechnologies to Participate in Virtual Fireside Chat With Canaccord Genuity on May 20, 2021
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer...
May 13, 2021 11:15 am ET
Announcements in Conjunction With Theratechnologies Annual Meeting
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today held its annual meeting of shareholders. As part of the...
Apr 14, 2021 07:30 am ET
Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the...
Apr 12, 2021 04:30 pm ET
Theratechnologies to Present at the Bloom Burton & Co. Healthcare Investor Conference
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer...
Apr 12, 2021 01:46 pm ET
Theratechnologies to Announce Financial Results for Its First Quarter Fiscal 2021
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the first...
Apr 10, 2021 10:02 am ET
Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new in vivo preclinical data were presented at the 2021...
Mar 29, 2021 01:00 pm ET
Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets
Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the addition...
Mar 24, 2021 07:30 am ET
Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its...
Mar 20, 2021 11:00 am ET
Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect on Immune Response Linked to Liver Inflammation
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new data, demonstrating the positive effect of...
Mar 10, 2021 04:30 pm ET
Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new positive pre-clinical data on TH1902, its...
Feb 25, 2021 04:43 pm ET
Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer,...
Feb 25, 2021 07:30 am ET
Theratechnologies Announces Fourth Quarter and Fiscal Year 2020 Financial Results
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced its financial results for the fourth quarter and...
Feb 11, 2021 10:21 am ET
Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced, today that it will issue its financial results for the fourth...
Feb 04, 2021 07:30 am ET
Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration...
Jan 19, 2021 09:41 am ET
Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the closing of its...
Jan 19, 2021 09:40 am ET
Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the closing of its...
Jan 14, 2021 09:49 am ET
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and...
Jan 11, 2021 08:19 pm ET
Theratechnologies Announces US$40 Million Bought-deal Public Offering of Units
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has entered into an...
Jan 11, 2021 07:13 pm ET
Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has entered into an...
Jan 07, 2021 07:00 am ET
Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities
Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced net revenue estimates for its fourth quarter and...
Dec 08, 2020 07:00 am ET
Theratechnologies Announces New Findings for its Lead Investigational Compound TH1902 for the Treatment of Several Additional Cancers
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced new pre-clinical in vivo findings regarding the efficacy and...
Nov 23, 2020 04:01 pm ET
Theratechnologies to Present at the Piper Sandler Virtual Healthcare Conference
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that some of its management team members will be...
Nov 16, 2020 10:30 am ET
Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASH
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin...
Nov 06, 2020 01:35 pm ET
Theratechnologies Announces that Data on the Mechanism of Effect of Tesamorelin in NAFLD will be Presented at The Liver Meeting® 2020
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that an oral presentation including data on the mechanism of...
Nov 03, 2020 04:01 pm ET
Theratechnologies Announces Departure of Chief Commercial Officer
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Jovan Antunovic, Senior Vice President and Chief...
Oct 22, 2020 04:09 pm ET
Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming...
Oct 16, 2020 07:30 am ET
Theratechnologies Appoints Two New Board Members
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as...
Oct 15, 2020 07:00 am ET
Theratechnologies Announces Financial Results for the Third Quarter of Fiscal 2020
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced its financial results for the third quarter of...
Oct 13, 2020 04:37 pm ET
Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASH
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Patent and Trademark Office...
Oct 05, 2020 04:01 pm ET
Theratechnologies to Announce Financial Results for Third Quarter 2020
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2020 on Thursday, October 15, 2020. A conference call will be held on October 15,...
Sep 30, 2020 04:01 pm ET
Theratechnologies to Present at the H.C. Wainwright 4th Annual NASH Investor Conference on October 5
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Dr. Christian Marsolais, Senior Vice President and Chief...
Sep 21, 2020 07:30 am ET
Theratechnologies Announces Preliminary Third-Quarter Fiscal 2020 Financial Results
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced select preliminary financial results for the third quarter...
Sep 10, 2020 07:30 am ET
Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development...
Sep 10, 2020 02:00 am ET
Theratechnologies Announces Launch of Trogarzo® in Germany
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in...
Jul 30, 2020 07:30 am ET
Theratechnologies to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe Dubuc, the Senior Vice President and Chief Financial Officer of Theratechnologies, will present at the...
Jul 23, 2020 04:01 pm ET
Theratechnologies Reports That Tesamorelin Improves Liver Health
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce new data that further support the potential role of tesamorelin in the treatment of HIV-associated...
Jul 16, 2020 12:23 pm ET
Announcements in Conjunction With Theratechnologies Annual Meeting
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of shareholders. As part of the meeting, shareholders proceeded to elect the below candidates to the...
Jul 15, 2020 07:30 am ET
Theratechnologies Announces Financial Results for the Second Quarter of Fiscal 2020
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the second quarter of fiscal 2020 ended May 31, 2020. “While the COVID-19...
Jul 07, 2020 07:30 am ET
Theratechnologies Confirms Bioequivalence of New Tesamorelin Formulation
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that it has successfully completed a bioequivalence study evaluating a new formulation of tesamorelin compared...
Jul 06, 2020 07:30 am ET
Theratechnologies Announces Ibalizumab Inhibits HIV-2 In Vitro
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 23rd International AIDS Conference virtual meeting, demonstrates that ibalizumab is...
Jun 22, 2020 07:30 am ET
New Data Show Theratechnologies’ SORT1+ Technology is Effective in Many Treatment-Resistant Cancers
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology...
May 15, 2020 07:30 am ET
Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced new positive results for its investigational Sortilin (SORT1) targeting peptide-drug conjugates (PDCs) which will be...
May 12, 2020 07:30 am ET
Theratechnologies to Present at the RBC Capital Markets Global Healthcare Conference on May 19, 2020
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that management will present at the RBC Global Healthcare Conference on Tuesday, May 19, 2020 at 9:10 a.m. ET.  The...
Apr 27, 2020 07:30 am ET
Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that new positive results about its two investigational peptide-drug conjugates (PDC) TH1902 and TH1904 will be...
Apr 16, 2020 03:23 pm ET
Theratechnologies to Make Oral Presentation on Oncology Platform During AACR Virtual Annual Meeting
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it will make an oral presentation on new results from its sortilin targeting oncology platform during a virtual...
Apr 16, 2020 07:30 am ET
Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421...
Apr 14, 2020 07:30 am ET
Theratechnologies Announces Financial Results for the First Quarter of 2020
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the first quarter ended February 29, 2020. First quarter 2020 financial highlights First...
Mar 31, 2020 07:30 am ET
THERATECHNOLOGIES PROVIDES BUSINESS UPDATE RELATED TO CURRENT COVID-19 SITUATION
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today issued an update on the Company’s activities in relation to the current worldwide COVID-19 pandemic. “Theratechnologies’...
Mar 11, 2020 12:00 pm ET
Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIV
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that Dr. Lindsay Fourman, from Harvard Medical School, presented data demonstrating that visceral fat is a...
Mar 02, 2020 07:00 am ET
Change to Theratechnologies Management
Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring
Feb 25, 2020 07:30 am ET
Theratechnologies Announces Financial Results for Fiscal Year 2019
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the year ended November 30, 2019. Fiscal Year 2019 Financial Highlights Record revenue...
Feb 18, 2020 08:00 am ET
Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the fourth quarter and fiscal year ended November 30, 2019, on Tuesday, February 25, 2020. A conference call will be held on...
Feb 04, 2020 07:30 am ET
Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon...
Dec 19, 2019 09:06 am ET
Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today provided preliminary revenue estimates for its recently completed fiscal year 2019 and revenue guidance for fiscal year 2020....
Dec 13, 2019 07:30 am ET
Theratechnologies’ Oncology Platform Improves Efficacy and Tolerability of Docetaxel in Vivo and in Vitro
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to report on new data presented today at the San Antonio Breast Cancer Symposium (SABCS). Results from in vitro and in...
Nov 27, 2019 10:59 am ET
Theratechnologies’ CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will attend the 31st Annual Healthcare Conference starting at 12:30 p.m. on December 3rd, 2019 at the...
Nov 25, 2019 07:30 am ET
Theratechnologies Starts Commercialization of New EGRIFTA SVᵀᴹ in the United States
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that EGRIFTA SVᵀᴹ (2mg/vial) is now commercially available in the United States. Our salesforce has started...
Nov 14, 2019 03:28 pm ET
Theratechnologies’ CFO to Attend Stifel Healthcare Conference in New York City
Theratechnologies Inc. (Theratechnologies) (TSX: TH), a commercial-stage biopharmaceutical company, is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer, will attend the Stifel Healthcare Conference which...
Nov 07, 2019 07:30 am ET
Trogarzo® Remains Effective Close to a Decade After Treatment Initiation
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 17th European AIDS Conference, currently being held in Basel, Switzerland,...
Oct 21, 2019 07:30 am ET
Theratechnologies Provides Details About R&D Day Webcast
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (NASDAQ: THTX) (TSX: TH), a commercial-stage pharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased...
Oct 14, 2019 10:49 am ET
REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX) is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the...
Oct 11, 2019 06:30 pm ET
Tesamorelin Study Results on NAFLD Published in Lancet HIV
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX) is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the...
Oct 10, 2019 07:30 am ET
Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing 
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH), a commercial-stage biopharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased to announce...
Oct 08, 2019 07:30 am ET
Theratechnologies Announces Financial Results for the Third Quarter of 2019
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the third quarter ended August 31, 2019. Third quarter 2019 financial highlights • Third quarter net sales of $16,111,000, up 19.3% from the same...
Oct 04, 2019 01:00 pm ET
1.7 Million Dollars Grant Towards Development of Theratechnologies’ Targeted Oncology
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute to a grant totaling...
Oct 03, 2019 08:17 am ET
New 48-Week Data Presented at IDWeek Show Trogarzo® Remains Safe and Effective
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that new 48-week data from the TMB-311 extension study confirm that Trogarzo® provides durable viral suppression and a safety profile consistent with the 24-week pivotal...
Oct 01, 2019 02:14 pm ET
Theratechnologies to Announce Financial Results for Third Quarter 2019
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2019, on Tuesday, October 8, 2019. A conference call will be held on October 8, 2019 at 8:30 a.m....
Sep 30, 2019 12:18 pm ET
Theratechnologies to Present at Cantor Fitzgerald Global Healthcare Conference in New York City
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will make a presentation at the 2019 Cantor Fitzgerald Global Healthcare Conference on October 2,...
Sep 26, 2019 02:13 pm ET
European Commission Approves Trogarzo®
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo® (ibalizumab) was approved today by the European Commission. “The approval of Trogarzo® by the European Commission represents a historical milestone for...
Sep 26, 2019 10:29 am ET
Theratechnologies Included in the First TSX30 Ranking
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it ranked 21st on the first TSX30 ranking of top performers on the Toronto Stock Exchange. The ranking was established based on the following criteria: Corporate...
Sep 26, 2019 09:00 am ET
Toronto Stock Exchange Introduces the TSX30
Canada's premier equities marketplace launches new program to showcase top performing companies, TSX to host market open ceremony September 27
Sep 19, 2019 07:30 am ET
Theratechnologies Reaches Agreement With AIDS Drug Assistance Program (ADAP) for New EGRIFTA SV™
Theratechnologies Inc. (TSX: TH) is pleased to announce that an agreement has been reached with the AIDS Drug Assistance Program Crisis Task Force for EGRIFTA SVTM (tesamorelin for injection), which will commercially launch in the United States...
Sep 12, 2019 09:01 am ET
Theratechnologies Ranks Among Canada’s 500 Fastest Growing Companies
Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it has been recognized as 137th fastest growing Canadian companies over the last five years according to the 2019 Growth 500 ranking released today by Canadian...